GlassScriptPhysician profile
Adam Madl
NPI 1922413939
$10,929.28
in general payments reported to CMS, 2019-2025
20 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 77% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,535 · 2020: $2,033 · 2021: $823 · 2022: $82.04 · 2023: $884 · 2024: $991 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Travel and Lodging: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.13 |
| Travel and Lodging | $1,669.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,075.51 | 2019-2024 | Proclaim, Ionicrf, Eterna |
| Nalu Medical, INC. | $1,499.69 | 2020-2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $1,483.47 | 2019-2020 | |
| Vertos Medical, INC. | $841.34 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $792.30 | 2025 | Iovera |
| Vertiflex, INC. | $659.27 | 2019 | |
| Stryker Corporation | $507.82 | 2025 | Mild Device Kit |
| Nevro Corp. | $249.34 | 2019-2021 | |
| Saluda Medical Americas, INC. | $181.47 | 2025 | Evoke |
| Medtronic, INC. | $123.94 | 2023 | Synchromedii |
| Spr Therapeutics, INC | $81.25 | 2023 | Sprint Pns System |
| Abbvie INC. | $78.35 | 2021 | |
| Collegium Pharmaceutical, INC. | $78.29 | 2019 | |
| Mml US, INC. | $67.03 | 2023-2025 | Reactiv8 |
| Boston Scientific Corporation | $61.93 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.42 | 2020 | |
| Tersera Therapeutics LLC | $33.79 | 2020 | |
| Averitas Pharma INC. | $27.98 | 2025 | Qutenza |
| Pfizer INC. | $17.41 | 2021 | |
| Relievant Medsystems, INC. | $16.68 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Madl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.